Costantino Mancusi1, Guido Grassi2, Claudio Borghi3, Stefano Carugo4, Francesco Fallo5, Claudio Ferri6, Cristina Giannattasio2,7, Davide Grassi6, Claudio Letizia8, Pietro Minuz9, Maria Lorenza Muiesan10,11, Stefano Perlini12,13, Giacomo Pucci14, Damiano Rizzoni10, Massimo Salvetti10, Riccardo Sarzani15,16, Leonardo Sechi17, Franco Veglio18, Massimo Volpe19,20, Guido Iaccarino1. 1. Department of Advanced Biomedical Sciences, Federico II University, Naples. 2. Department of Medicine and Surgery, University of Milan-Bicocca. 3. Department of Medicine and Surgery Sciences, Alma Mater Studiorum University of Bologna. 4. Health Sciences Department, University of Milan. 5. Clinica Medica 3, Department of Medicine, University of Padova. 6. Department of Clinical Medicine, Public Health, Life and Environment Sciences, University of L'Aquila. 7. Cardiology 4, 'A. De Gasperis' Department, ASST GOM Niguarda Ca' Granda Hospital, Milan. 8. Department of Translational and Precision Medicine, Unit of Secondary Arterial Hypertension, 'Sapienza' University of Rome, Policlinico 'Umberto I', Rome. 9. Department of Medicine, Section of Internal Medicine C, University of Verona. 10. Department of Clinical & Experimental Sciences, University of Brescia. 11. Medicina 2, ASST Spedali Civili Brescia. 12. Department of Emergency, IRCCS Policlinico San Matteo Foundation, Pavia. 13. Department of Internal Medicine and Therapeutics, University of Pavia. 14. Unit of Internal Medicine, AOU Santa Maria - Department of Medicine, University of Perugia, Terni. 15. Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University 'Politecnica Delle Marche', Ancona. 16. Italian National Research Centre on Aging, Hospital 'U. Sestilli', IRCCS-INRCA, Ancona. 17. Department of Medicine, University of Udine. 18. Division of Internal Medicine and Hypertension, Department of Medical Sciences, AOU Città Salute e Scienza Torino, University of Torino. 19. Clinical and Molecular Medicine Department, Sapienza University Sant'Andrea Hospital, Rome. 20. IRCCS Neuromed, Pozzilli (IS), Italy.
Abstract
OBJECTIVE: The burst of COVID-19 epidemics in Italy prompted the Italian Society of Hypertension to start an observational study to explore the characteristics of the hospitalized victims of the disease. The current analysis aimed to investigate the predictors of healing among Italian COVID-19 patients. We also assessed the effect of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers on the outcome. METHODS: We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to explore the demographic and clinical characteristics of patients with confirmed COVID-19 infection. We analyzed information from 2446 charts of Italian patients admitted for certified COVID-19 in 27 hospitals. Healing from COVID-19 infection, defined as two consecutive negative swabs, was reported in 544 patients (22.2%), 95% of them were hospitalized. RESULTS: Age and Charlson Comorbidity Index were significantly lower in healing compared with nonhealing patients (63 ± 15 vs. 69 ± 15 and 2 ± 2 vs. 3 ± 2, both P < 0.05). In multivariable regression model, predictors of healing were younger age (OR: 0.99; 95% CI 0.98-0.99, P = 0.0001), absence of chronic kidney disease (OR: 0.35; 95% CI 0.17-0.70, P = 0.003) or heart failure (OR: 0.44; 95% CI, 0.28-0.70, P = 0.001). In the subgroup of patients suffering from hypertension and/or heart failure (n = 1498), no differences were observed in the use of ACE inhibitors and angiotensin receptor blockers. CONCLUSION: Our study demonstrated that younger age and absence of comorbidities play a major role in determining healing in patients with COVID-19. No effects of ACE inhibitors and angiotensin receptor blockers on the outcome was reported.
OBJECTIVE: The burst of COVID-19 epidemics in Italy prompted the Italian Society of Hypertension to start an observational study to explore the characteristics of the hospitalized victims of the disease. The current analysis aimed to investigate the predictors of healing among Italian COVID-19patients. We also assessed the effect of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers on the outcome. METHODS: We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to explore the demographic and clinical characteristics of patients with confirmed COVID-19infection. We analyzed information from 2446 charts of Italian patients admitted for certified COVID-19 in 27 hospitals. Healing from COVID-19infection, defined as two consecutive negative swabs, was reported in 544 patients (22.2%), 95% of them were hospitalized. RESULTS: Age and Charlson Comorbidity Index were significantly lower in healing compared with nonhealing patients (63 ± 15 vs. 69 ± 15 and 2 ± 2 vs. 3 ± 2, both P < 0.05). In multivariable regression model, predictors of healing were younger age (OR: 0.99; 95% CI 0.98-0.99, P = 0.0001), absence of chronic kidney disease (OR: 0.35; 95% CI 0.17-0.70, P = 0.003) or heart failure (OR: 0.44; 95% CI, 0.28-0.70, P = 0.001). In the subgroup of patients suffering from hypertension and/or heart failure (n = 1498), no differences were observed in the use of ACE inhibitors and angiotensin receptor blockers. CONCLUSION: Our study demonstrated that younger age and absence of comorbidities play a major role in determining healing in patients with COVID-19. No effects of ACE inhibitors and angiotensin receptor blockers on the outcome was reported.
Authors: Francesco Spannella; Federico Giulietti; Chiara Di Pentima; Massimiliano Allevi; Valentina Bordoni; Andrea Filipponi; Sara Falzetti; Caterina Garbuglia; Samuele Scorcella; Piero Giordano; Riccardo Sarzani Journal: Front Cardiovasc Med Date: 2022-06-17